156478-71-6 Usage
General Description
4-Boc-1-piperazineacetic acid, also known as tert-butyl 1-piperazineacetate, is an organic chemical compound with the molecular formula C14H24N2O4. 4-Boc-1-piperazineacetic acid, available in a white to off-white crystalline powder form, belongs to the chemical class of piperazines; organic compounds containing a piperazine ring, which is a saturated aliphatic six-member ring with two nitrogen atoms at opposite positions. It is frequently used as an intermediate in the pharmaceutical industry, particularly in the synthesis of active pharmaceutical ingredients. Its stability, reactivity, and associated health hazards are typical of piperazine compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 156478-71-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,4,7 and 8 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 156478-71:
(8*1)+(7*5)+(6*6)+(5*4)+(4*7)+(3*8)+(2*7)+(1*1)=166
166 % 10 = 6
So 156478-71-6 is a valid CAS Registry Number.
InChI:InChI=1/C11H20N2O4/c1-11(2,3)17-10(16)13-6-4-12(5-7-13)8-9(14)15/h4-8H2,1-3H3,(H,14,15)
156478-71-6Relevant articles and documents
METALLOENZYME INHIBITOR COMPOUNDS
-
, (2018/07/29)
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
PROTEIN KINASE INHIBITORS
-
, (2013/04/25)
A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
NK1 and NK3 antagonists
-
Page/Page column 27, (2010/02/14)
The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.
